The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia
| Autor: | Adrián Mosquera Orgueira, Gerardo Musuraca, Giovanni Martinelli, Giorgia Simonetti, Claudio Cerchione, Maria Benedetta Giannini, Gianmarco Bagnato, Giovanni Marconi |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty medicine.drug_class medicine.medical_treatment Antineoplastic Agents Newly diagnosed 030204 cardiovascular system & hematology Tyrosine-kinase inhibitor 03 medical and health sciences chemistry.chemical_compound fluids and secretions 0302 clinical medicine hemic and lymphatic diseases Internal medicine medicine Humans Pharmacology (medical) Midostaurin Benzothiazoles neoplasms Protein Kinase Inhibitors Quizartinib Randomized Controlled Trials as Topic Chemotherapy Aniline Compounds business.industry Phenylurea Compounds Myeloid leukemia hemic and immune systems General Medicine Staurosporine Safety profile Leukemia Myeloid Acute chemistry fms-Like Tyrosine Kinase 3 030220 oncology & carcinogenesis Pyrazines embryonic structures Relapsed refractory business |
| Zdroj: | Expert opinion on drug safety. 20(7) |
| ISSN: | 1744-764X |
| Popis: | FLT3 inhibitors are important drugs in the therapy of FLT3 positive acute myeloid leukemia (AML). Midostaurin was registered in combination with chemotherapy to treat newly diagnosed AML. Gilteritinib and quizartinib demonstrate effectiveness in a randomized trial in relapsed/refractory AML. Several promising FLT3 inhibitors are being evaluated in clinical research.This review will report the safety of FLT3 inhibitors that are registered for acute myeloid leukemia induction and rescue therapy.In the near future, it is possible that all the FLT3 positive non M3-AML patients will receive a FLT3 inhibitor. Therapy adherence and strategies to mitigate adverse events must be pursued. The treatment with FLT3 inhibitors may be optimized in terms of toxicities with a rational evaluation of antifungal prophylaxis and concomitant therapy, cardiology monitoring, and keeping in mind rare adverse events. Future studies on unfit patients, special populations, and maintenance settings are warranted, together with post-market studies and real-life experiences. Whenever new FLT3 inhibitors will come to the clinic, we could face a scenario in which profound knowledge of effectiveness, toxicities, and off-target effects will be relevant to choose the best drug for each patient. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|